Patients with homologous-recombination-deficient advanced ovarian cancer alive at 5 years were twice as likely to be progression free with niraparib than placebo, although no long-term overall survival benefit was reported 

The phase II part of the ROCSAN trial failed to meet its primary endpoint but there may be potential for benefit based on efficacy and safety data with the combination

New survival data from the MIRASOL trial support the use of this antibody-drug conjugate as a preferred standard of care for patients with high folate receptor alpha tumour expression

While updated results from the DUO-O trial appear promising, they are not conclusive due to the study design

A multitude of new agents under development could finally offer meaningful treatment options to a patient population with high unmet need  

Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment 

Data from selected patients in the RUBY trial show improvements in QoL domains over the course of treatment and benefits compared with placebo 

Results from the RUBY trial show improvements both in progression-free survival and overall survival in patients treated with dostarlimab plus standard chemotherapy, indicating a new standard of care  

Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer